The randomized phaseII study about the skin hazard mitigation in the Erlotinib + oral steroid agent combined therapy and Erlotinib to non-small cell lung cancer patients

Phase 2

• Conditions: on-small cell lung cancer

• Registration Number: JPRN-UMIN000007307
• Lead Sponsor: Respiratory Medicine, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-02-16
• Study Completion: 2014-03-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Not provided

Exclusion Criteria

1. History of severe drug allergy 2.Prior treatment with drugs (Gefitinib or Cetuximab)which act on an EGFR system. 3.The patient by whom revelation of a critical adverse event is expected with a prednisolone tablet 4. Pregnant or breast-feeding females 5.Patient of the past of an active interstitial lung obstacle or a merger 6. Uncontrollable infectious disease 7. Uncontrollable peptic ulcer 8. Glaucomatous patient 9. Patient of serious illness skin disease 10. The patient who has critical complications. (Uncontrollable cardiac disease, liver cirrhosis, continuous watery diarrhea) 11. The patient in whom oral ingestion is impossible. 12. Decision of ineligibility by a physician

Study & Design

• Study Type: Interventional
• Study Design: Not specified